Aspen Continues Chinese Voyage By Acquiring Sandoz’s Local Operations

Sandoz Sends Cash Back The Other Way, Buying Four Anesthetic Products In EEA

 
• By Dean Rudge

Aspen has underlined previously its commitment to building on its business in China, and now it has done so, picking up Sandoz’s local operations for up to €92.6m, while bringing in cash by offloading a quartet of anesthetics in Europe back to the firm.

Flags of China flying in Shanghai
• Source: Shutterstock

South Africa’s Aspen Pharmacare believes it has taken a “major step in our stated strategic objective of increasing our presence in China,” after striking a deal to acquire Sandoz’s business in China, including the unit’s pipeline and a portfolio of products, for up to €92.6m ($100m).

At the same time, Sandoz has agreed to strengthen its hospital drugs footprint after agreeing to buy from Aspen four anesthetics – Nimbex, Tracrium, Carbocaine and Naropin – currently sold by the firm in the European

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business